

# Cuff Leak and Airway Obstruction in Mechanically Ventilated ICU Patients (COMIC): A Pilot Randomized Controlled Trial

Kimberley Lewis<sup>1,2</sup>, Sarah Culgin<sup>3</sup>, Roman Jaeschke<sup>1,2,3,4</sup>, Dan Perri<sup>1,4,5</sup>, Corry Marchildon<sup>4</sup>, Kelly Hassall<sup>4</sup>, Yousef Almubarak<sup>6</sup>, Wojciech Szczeklik<sup>7</sup>, Thomas Piraino<sup>8</sup>, Lehana Thabane<sup>2,3</sup>, Khaled M. Alqahtani<sup>9</sup>, Abdulazez Alghamdi<sup>10</sup>, Mohammed Alshahrani<sup>6</sup>, Waleed Alhazzani<sup>1,2,3,4</sup>

<sup>1</sup> McMaster University, Department of Medicine, Hamilton, Canada; <sup>2</sup> McMaster University, Department of Health Research Methods, Evidence, and Impact, Hamilton, Canada; <sup>3</sup> St. Joseph's Healthcare, St. Joseph's Health Research Institute, Hamilton, Canada; <sup>4</sup> St. Joseph's Healthcare, Hamilton, Canada; <sup>5</sup> McMaster University, Clinical Pharmacology and Toxicology, Hamilton, Canada; <sup>6</sup> Imam Abdulrahman Bin Faisal University, Department of Critical Care, Dammam, Saudi Arabia; <sup>7</sup> Jagiellonian University Medical College, Department of Intensive Care and Perioperative Medicine, Krakow, Poland; <sup>8</sup> St. Michael's Hospital, Toronto, Canada; <sup>9</sup> Prince Sattam Bin Abdulaziz University, Department of Mathematics, Al-Kharj, Saudi Arabia; <sup>10</sup> King Fahad Hospital of the University, Imam Abdul Rahman bin Faisal University Respiratory Therapy Department, Dammam, Saudi Arabia

## INTRODUCTION

- Intubation and invasive mechanical ventilation can be lifesaving interventions
- However, one of the known complications of intubation is laryngeal edema<sup>1</sup>
- Up to 10.5% of patients with LE will fail extubation and require re-intubation<sup>2</sup>
- For multiple reasons, reintubation is associated with significant morbidity and mortality
- The cuff leak test is a non-invasive test that can be done at the bedside to detect laryngeal edema prior to extubation
- Unfortunately, the diagnostic accuracy of the CLT is questioned<sup>3</sup>


## AIM

- To address the feasibility of conducting an adequately powered trial to ultimately investigate the clinical utility of the CLT and its impact on patient-important outcomes.

## METHODS

- Studies protocol
  - Registered to ClinicalTrials.gov (Identifier: NCT03372707)
  - Full protocol published separately<sup>4</sup>
- Study design
  - International, multicentred, randomized, parallel-group trial
  - Ran in one Canadian, one Saudi Arabian, and one Polish centre
- Ethics
  - Local research ethics boards of participating centres approved of the study protocol
  - Canada and Saudi Arabia used a mixed consent model: *a priori* from next of kin when possible, otherwise deferred consent
  - Poland used waived consent
- Inclusion criteria
  - Mechanically ventilated adults >18yo admitted to the ICU and an order to extubate has been provided by the treating physician
- Exclusion criteria
  - 1) Palliative; 2) Pregnant; 3) Known airway injury (e.g. smoke inhalation, head and neck surgeries, admitted with airway edema, self extubation event); 4) Difficult or traumatic intubation; 5) Known pre-existing trachea-laryngeal abnormalities; 6) Mechanically ventilated through a tracheostomy; 7) Failed extubation within current ICU admission; 8) History of airway obstruction; 9) Failed CLT within 24 hours prior to enrollment; 10) ICU physician declines enrollment
- Randomisation
  - 1:1 allocation by central computer of undisclosed variable block sizes
  - Randomisation stratified by: 1) ETT size <8mm or 8mm; 2) >7 days vs ≤7 day duration of mechanical ventilation prior to randomization and; 3) Study site
- Outcomes
  - Primary: Feasibility
  - Secondary: Clinical

- Intervention
  - All patients undergo a CLT by an unblinded study RT (Figure 1)
  - In the intervention group, the results were communicated to the treating team. The team could elect to administer corticosteroids, diuretics, withhold extubation, any combination of the aforementioned options, or simply extubate
  - In the control arm, the results of the CLT were not communicated to the treating team (whether passed or failed) and the patient was extubated regardless of results



## RESULTS

### 1. Patient characteristics

- From July 2018 to July 2019 we screened a total of 716 patients who were being treated in the three participating ICUs
- 507 were not eligible (Table 1)
- 109 eligible but not enrolled (Table 2)

Reason for ineligibility	Proportion of patients- no. (%)
Not Intubated	304 (60.0)
Palliative care plan or plan of care does not include reintubation	41 (8.1)
Known pregnancy	2 (0.4)
Mechanical ventilation via a tracheostomy	69 (13.6)
Difficult or traumatic intubation	42 (8.3)
Known pre-existing tracheolaryngeal abnormalities	10 (2.0)
Smoke inhalation/facial burns	1 (0.2)
History of post-extubation airway obstruction	4 (0.8)
Under 18 years of age	2 (0.4)
Failed extubation attempt in the current ICU admission	9 (1.8)
Admitted with laryngeal edema	17 (3.4)
Other	6 (1.8)
Total	507

Table 1: Reasons for ineligibility

- Of 100 eligible patients, 56 randomised to intervention arm and 44 to control arm (Figure 2, Table 3)




Figure 2: Consort diagram

Reason for eligible but not enrolled	Proportion of patients- no. (%)
Extubated outside screening schedule	56 (51.3)
Patient or SDM Declined enrollment	12 (11.0)
ICU physician declined enrollment	1 (0.9)
Family not approached due to stressful situations or language barriers	7 (6.4)
Already had a CLT performed prior to enrollment	11 (10.1)
Other (e.g. patient died, self extubated, transferred to another hospital, etc).	22 (20.2)
Total	109

Table 2: Reasons for eligible but not enrolled

Characteristic	Results of CLT communicated (n=56)	Results of CLT not communicated (n=44)
Age-Yr.	57.7±16.3	66.2±16.5
Female sex—no. (%)	33 (41.1)	21 (47.7)
BMI	28.5±8.3	28.0±9.1
Size of ETT-mm	7.7±0.5	7.6±0.4
APACHE II Score*	19.3±8.6	20.0±8.0
Patient type—no. (%)		
Medical	37 (66)	18 (40.9)
Surgical	19 (33.9)	26 (59.1)
Admitting diagnosis—no. (%)		
Cardiovascular	4 (7.1)	5 (11.4)
Respiratory	20 (35.7)	12 (27.3)
Gastrointestinal	11 (19.6)	13 (29.5)
Neurologic	4 (7.1)	4 (9.1)
Sepsis	8 (14.3)	4 (9.1)
Trauma	1 (1.8)	1 (2.3)
Renal	3 (5.4)	3 (6.8)
Other medical	3 (5.4)	1 (2.3)
Other surgical	2 (3.6)	1 (2.3)
Median time from intubation to randomisation-days (IQR)	2.7 IQR (1.5-5.1)	2.9 IQR (1.4-6)
Reason for mechanical ventilation—no. (%)		
Hypoxia	17 (30.4)	13 (29.5)
Inability to protect airway	25 (44.6)	23 (52.3)
Prophylactic intubation	8 (14.3)	3 (6.8)
Hypercapnia	6 (10.7)	5 (11.4)
Medications administered during admissions-no. (%)		
Propofol	37 (66.1)	33 (75.0)
Opioid	42 (75.0)	36 (81.8)
Benzodiazepines	27 (48.2)	22 (50.0)
Vasopressor	30 (53.6)	24 (54.5)
Paralytic	3 (5.4)	4 (9.1)
Inotrope	1 (1.8)	2 (4.6)
Physiologic parameters at the time of extubation		
PaO <sub>2</sub> -mmHg	86.3±23.6	98.0±41.5
Arterial pH	7.4±0.06	7.4±0.05
PfO <sub>2</sub> (%)	30 IQR (30-39)	30 IQR (27.3-33.3)
PEEP-cm of water	6 IQR (5-6-25)	6 IQR (5-8)
HR-beats per minute	89.2±17.9	91.5±18.8
Mean arterial pressure-mmHg	90.5±17.4	90.3±15.1
Glasgow coma scale	12 IQR (11-15)	12.5 IQR (10-14)

Table 3: Enrolled patients' baseline characteristics

### 2. Primary outcome: Feasibility

- All feasibility criteria met pre-defined success thresholds (Table 4)

Feasibility Outcome	Criteria for Success of Outcome	Estimates (95% CI where applicable)
Consent rate	≥70% of SDMs or patients approached providing consent	88.3% (82.1 to 94.5%)
Recruitment rate	≥4 patients/month	7.6 patients/month
Protocol adherence	≥80% of patients assigned to the control arm being extubated immediately after the CLT	98% (95 to 100%)

Table 4: Feasibility criteria

### 3. Clinical Outcomes

- 93% of patients passed the CLT and 6% failed
- No significant difference between the groups in reintubation, duration of invasive mechanical ventilation, ICU length of stay, hospital length of stay, or 30 day mortality (Table 5)
- Reasons for reintubation are presented in Table 6

Outcome	Results of CLT communicated (n=56)	Odds ratio* or Mean Difference (95% CI)	Outcome	Results of CLT communicated (n=44)	Results of CLT not communicated (n=4)
Reintubation-no. (%)	4 (7.1)	4 (9.1)	0.77* (0.13-4.41)	Reason for reintubation	
Post-extubation stridor-no. (%)	2 (3.6)	0 (0.0)	--	Inability to protect airway -no. (%)	0 (0.0)
Clinically significant post-extubation stridor-no. (%)	2 (3.6)	0 (0.0)	--	Hypoxia -no. (%)	4 (100)
Mortality	2 (4.5)	10 (17.8)	0.22 (0.02 to 1.16)	Hypercapnia -no. (%)	0 (0.0)
Hospital LOS-days	22.77±13.01	24.74±13.08	0.94 (-3.04 to 6.49)	Airway obstruction -no. (%)	0 (0.0)
ICU LOS-days	10.13±9.52	9.84±9.41	-0.16 (-2.28 to 1.90)	Time from extubation to reintubation-days	1.55±0.61
Duration MV-days	2.76 IQR (1.61-5.27)	3.29 IQR (1.24-4.81)	-0.05 (-1.04 to 1.04)		0.23±0.25

Table 6: Reason for reintubation

Table 5: Clinical outcomes

## CONCLUSION

- Our results will likely support the feasibility of conducting a larger trial
- Although underpowered for clinical outcomes, there was no alarming increase in reintubations or surgical airway requirements
- Strengths of trial include: 1) This is the first RCT to identify that a powered trial will be feasible to determine; 2) This trial is international and multi-centered (including Poland which does not often order the CLT); 3) Mythological design to reduce bias with undisclosed variable block sizes and central allocation; 4) No loss to follow-up
- Limitations include: 1) Stratification with a small sample size resulted in imbalance; 2) Small event rate secondary to including some patients with no risk factors for laryngeal edema; 3) This was a pilot trial and therefore underpowered to detect any clinical outcomes
- A large RCT will help us to understand the risk and benefit of the CLT in critical illness and will impact practice around the world.

## REFERENCES

- Maury E et al. J Crit Care. 2004;19:23-8
- Zhou T, et al. J Evid Based Med. 2007;4:242-54.
- Girard TD, et al. Am J Respir Crit Care Med. 2017;195:120-33.
- Lewis K, et al. BMJ Open. 2019;9:e029394.

The authors have no conflicts of interest. Funding: Dr Paul O'Byrne McMaster University Internal Medicine Research Grant.